Bensedin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bensedin

Quick Facts

Property Description
Active ingredient Diazepam (INN)
Form Tablet, Injectable Solution, Rectal Suppository
Pharmacological class Benzodiazepine, CNS Depressant
General purpose Tranquilizer, Muscle Relaxant, Sedative
Origin Synthetic

What is Bensedin and its Active Composition?

Bensedin is a recognized trade designation for a medication whose active pharmaceutical ingredient is Diazepam (INN), which belongs to the Benzodiazepine class of drugs. It is a synthetic, single-ingredient product classified as a potent Central Nervous System (CNS) Depressant.

The compound Diazepam is the singular active substance in this formulation, manufactured entirely through chemical synthesis. It is characterized as a foundational medicine with global health utility. Diazepam’s effects stem from its capacity to enhance the action of the brain's main inhibitory neurotransmitter, Gamma-Aminobutyric Acid (GABA), which reduces the overall excitability of nerve cells.

What Class of Medicine Does Bensedin Belong To?

Bensedin is functionally classified as an anxiolytic, a sedative-hypnotic, an anticonvulsant, and a skeletal muscle relaxant. This multi-faceted pharmacological profile reflects its clinically established ability to address conditions characterized by acute neurological overactivity or significant physical tension.

The medication is supplied in multiple dosage forms, including the common oral tablet and the rapid-acting injectable solution for parenteral administration. This form versatility is a key differentiating factor, making the active substance, Diazepam, adaptable for both maintenance therapy and urgent situational use. Its general therapeutic purpose is to achieve a controlled state of physical and psychological tranquility and sedation, providing relief from severe agitation and central muscle spasms caused by excessive signaling within the nervous system, such as during episodes of acute withdrawal.

Regulatory References

  1. WHO Essential Medicines List - Diazepam entry

What side effects are possible with Bensedin?

The safety profile of Bensedin (Diazepam) is officially documented by government health authorities, focusing on adverse effects, frequency classifications, and necessary safety constraints.

Adverse Reaction Scope

The most commonly classified adverse reactions reflect the drug's action as a Central Nervous System (CNS) depressant. Officially listed effects include drowsiness, fatigue, and ataxia (poor coordination), which are frequently noted as being more pronounced at the start of therapy.

Adverse effects are grouped by body system, including Nervous System Disorders (e.g., tremor, dizziness, slurred speech) and Psychiatric Disorders (e.g., confusion, changes in libido). Paradoxical reactions, such as excitement, agitation, or rage, are also officially listed and may require discontinuation.

Serious Safety Risks and Constraints

Regulatory documents emphasize the risk of respiratory depression, which is heightened when the medication is used concurrently with other CNS depressants, including alcohol. Serious hepatic issues like jaundice have also been reported.

Risks of dependence and withdrawal syndrome are explicitly documented, with the likelihood increasing with higher dosages and longer durations of exposure. Abrupt cessation following chronic use may precipitate acute withdrawal symptoms.

Safety is specifically addressed for certain populations:

  • Older Adults: Increased susceptibility to sedation and ataxia is noted, requiring particular caution.
  • Impairment: Use is contraindicated in severe hepatic insufficiency and severe respiratory insufficiency.
  • Infants: Use is contraindicated in pediatric patients under 6 months of age due to insufficient clinical experience.

The medication is formally restricted for use in patients with conditions such as myasthenia gravis and sleep apnoea syndrome.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose manifestations ranging from mild to severe Central Nervous System (CNS) depression, all of which require immediate medical attention.

Documented Overdose Presentations

Category Official Regulatory Statement
Documented overdose presentations Overdose symptoms are documented to range from mild to severe CNS depression, including drowsiness, somnolence, confusion, ataxia, hypotonia, diminished reflexes, and dysarthria.
Serious / Life-Threatening Outcomes The most significant risks are respiratory depression, apnea, and coma, particularly in cases of co-ingestion with other CNS depressants, such as alcohol.
Population-Specific Notes Overdose effects are noted to be generally more severe in geriatric patients and in individuals with pre-existing respiratory or hepatic impairment (Source: EMA SmPC).

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Emergency management is primarily symptomatic and supportive treatment, requiring continuous clinical observation and monitoring of vital signs (Source: NIH MedlinePlus). The benzodiazepine antagonist Flumazenil is a documented treatment option, though regulatory guidance cautions that its use carries a risk of precipitating seizures.

Therapeutic Uses of Bensedin

The primary role of Bensedin (Diazepam) is to provide symptomatic support and is applied across therapeutic contexts involving symptoms of increased neurological or muscular activity. This medication is commonly used across its core therapeutic areas, relevant in clinical settings marked by heightened patient distress and where short-term symptomatic assistance is needed. The medication is considered relevant in conditions characterized by periods of heightened symptoms, including management of acute anxiety, symptomatic relief of muscle spasms, assistance in addressing severe recurrent seizures, and support during acute alcohol withdrawal.

“The application of supportive relief can help reduce the overall burden of symptoms during difficult, acute episodes.”

Managing Severe Acute Anxiety and Agitation

This medication is commonly used to help manage symptoms that create noticeable physiological strain, such as severe anxiety, debilitating worry, and acute psychomotor restlessness. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, and provides support that helps ease the overall symptom burden during difficult episodes, which assists with maintaining functional stability.


Quick Fact: Relief for Acute Physical and Psychological Distress
Primary Domains Anxiety, Muscle Spasm, Seizure, Acute Withdrawal
Symptom Focus Tension, Tremor, Agitation, Rigidity
Benefit Supports maintaining functional stability during symptomatic phases

Regulatory References

  1. NIH’s National Center for Biotechnology Information (NCBI) overview

Eligibility and Restrictions for Use

Eligibility for Bensedin (Diazepam) — Official Regulatory Information

The eligibility profile for Bensedin is strictly defined by regulatory documents, listing absolute prohibitions and populations requiring conditional use. Use is contraindicated in patients with a known hypersensitivity to benzodiazepines, Myasthenia Gravis, and specific serious medical conditions including severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnea syndrome.

Population Group Eligibility Status
Pediatric patients < 6 months Contraindicated (safety not established)
Older Adults (Geriatric) Use with caution (reduced starting dose required)
Pregnancy (Late Term) Not recommended (risk of neonatal withdrawal/flaccidity)
Breastfeeding Mothers Not recommended (drug passes into milk)

Use is also severely restricted for patients with a history of alcohol or drug dependence, as the medicine carries a risk of abuse, misuse, and addiction. Individuals with mild to moderate hepatic or renal impairment may be eligible but require careful monitoring and dose adjustment due to slower drug clearance. These strict criteria define who can and cannot use Bensedin, serving as a mandate for safe prescribing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Bensedin (Diazepam) is primarily structured around two clinically significant areas: additive central nervous system (CNS) depression and metabolic clearance modification, as officially documented in regulatory labeling.

Official Regulatory Interaction Constraints

Feature Interaction Context
Pharmacodynamic Enhancement Co-administration with Opioids and other CNS Depressants (e.g., alcohol, barbiturates, antipsychotics) is associated with an FDA Boxed Warning due to the risk of profound sedation, respiratory depression, and coma. Alcohol ingestion is advised against due to synergistic effects.
Metabolic Clearance Medicines that act as inhibitors of CYP2C19 and CYP3A4 enzymes (e.g., Cimetidine, Fluoxetine) are documented to reduce Diazepam elimination, increasing its plasma exposure and effects. Inducers of these enzymes (e.g., Rifampin) can reduce exposure.
Exposure Modification Valproic acid is officially noted to displace Diazepam from plasma protein binding sites, leading to an increase in the free, active drug fraction.
Absorption Constraint Ingestion with a moderate fat meal is documented to cause a delay and decrease in the drug's absorption.
Population Note Extreme caution is necessary for elderly patients and those with limited pulmonary reserve when co-administered with other CNS depressants, due to heightened risk of adverse respiratory events.

The overall regulatory framework emphasizes restricting co-administration with other depressant substances and adjusting for known metabolic or absorption modifiers to manage exposure levels.

Mechanism of Action

How Bensedin Works

Modulation of the Core Inhibitory System

The primary mechanism of action involves the binding of the active substance to an allosteric site on the GABA A receptor complex, the principal inhibitory neurotransmitter receptor in the central nervous system (CNS). The drug acts as a positive allosteric modulator, which enhances the effect of the endogenous neurotransmitter GABA. This interaction contributes to an increased inhibitory tone within targeted neural pathways.


Cascade Leading to Reduced Neuronal Excitability

The enhancement of GABA binding facilitates the increased flow of negatively charged chloride ions ( Cl^-) across the neuronal membrane and into the post-synaptic neuron. This accumulation of negative charge causes the nerve cell to become hyperpolarized. This core mechanistic cascade results in changes to physiological functions, leading to a reduction in the firing rate of overactive neurons by making the cell membrane less responsive to excitatory stimuli.


System-Level Physiological Modulation

The resulting widespread increase in inhibitory tone across the CNS modulates key regulatory systems in the brain, such as the limbic system, and influences spinal cord pathways. This mechanism results in changes to physiological functions, including a general reduction in overall neural excitability and a decrease in activity within spinal reflex arcs controlling skeletal muscle activity.

Dosage and Administration Information

Bensedin (Diazepam) is administered through multiple routes tailored to the clinical context, including oral forms (tablet and solution), intravenous (IV) and intramuscular (IM) injection, and specialized rectal or intranasal devices for acute, episodic use. The choice of route is often dictated by the need for speed, with IV injection preferred over the IM route due to the variable absorption associated with the latter.

The medication's usage protocol is highly constrained by established dosing and duration limits. Standard adult oral dosing ranges typically from 2 mg to 10 mg per dose, taken two to four times daily. For acute intervention, such as in status epilepticus, the IV dose is carefully titrated up to a maximum of 30 mg total. The administration of the injectable form requires a very slow injection rate (e.g., not exceeding 5 mg per minute) to ensure safe delivery.

Official instructions mandate specific procedural rules. Oral absorption may be delayed and decreased when taken with food, and the liquid concentrate must be diluted and consumed immediately. Importantly, the duration of use must be as short as possible, with the total course, including the gradual tapering process, generally not exceeding 8 to 12 weeks. A reduced initial dose is required for vulnerable groups, such as older adults and individuals with hepatic impairment. The dose must always be gradually reduced to cease treatment.

Recent Clinical Evidence

Research evidence / Overview of studies for Bensedin

Evidence for Use in Acute Anxiety and Agitation

The research exploring Bensedin was studied for its application in conditions characterized by fluctuating or unstable symptoms of anxiety and agitation and primarily involves randomized controlled trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time, applying standardized scales to monitor outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies over short-term intervals, typically two to four weeks. However, evidence quality varies across studies, and findings were mixed across the older and newer research. Long-term effects are not fully established, as there is limited information for long-term outcomes, and results apply only to the populations studied for acute symptomatic use.

Evidence for Use in Acute Alcohol Withdrawal Management

Bensedin was studied for its application in conditions associated with acute or disruptive episodes, specifically managing the symptoms of acute alcohol withdrawal syndrome (AWS). The evidence is derived from RCTs and clinical guidelines. Studies monitored outcomes describing episodic or acute changes, such as the severity of withdrawal symptoms and the prevention of acute complications like seizures or delirium.

Evidence contributes to understanding symptom patterns in this medication class for managing the acute phase. Data show patterns related to measured changes in symptom severity compared to placebo. Research provides insight into short-term changes during the acute phase but does not fully characterize management beyond the initial few days, as follow-up durations were limited.

Evidence for Use as an Adjunct for Muscle Spasm and Spasticity

This medication was evaluated in trials exploring its role as an adjunct for conditions marked by functional limitations due to skeletal muscle spasms. Research explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, as well as objective measures of muscle tone. Some trials reported how symptoms evolved in the observed populations when the medication was compared to placebo.

There is limited information for long-term outcomes related to its use for chronic spasticity, and some literature points to the possibility of diminished outcomes with extended use. Comparative evidence against common pain relievers for acute low back pain is also lacking.

Evidence for Use in Acute Repetitive Seizures

Bensedin was observed in studies focusing on episodes where symptoms become more noticeable, specifically for the intermittent management of acute repetitive seizure (ARS) episodes (seizure clusters). Research examined rapid-onset delivery methods. Studies reported how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to the time until the next seizure or intervention.

Results apply only to the populations studied for acute intervention. Long-term effects are not fully established for maintenance seizure control.

Long-Term Study Duration and Follow-up Data

Research has explored short-term symptom changes, with a vast majority of the core evidence derived from studies with a follow-up duration of just a few weeks. Long-term effects are not fully established, and data for certain groups remain insufficient for extended periods of continuous use. For acute indications, the research appropriately focuses only on the immediate, acute outcome.

Evidence in Special Populations

Research has been conducted that includes certain special populations, such as specific pediatric groups studied for spasticity and acute repetitive seizures. Older adults were included in some trials for anxiety and withdrawal, but subgroup findings are uncertain due to the specific characteristics of older populations examined in trials. For all special groups, the results apply only to the populations studied, and follow-up durations were limited.

What is Still Uncertain About Bensedin's Research Landscape

Major research limitations include the limited information for long-term outcomes across all approved uses. Comparative evidence against the newest alternative treatments is often lacking, as much of the core evidence base is older. Furthermore, evidence quality varies across studies, and some meta-analyses described a potential for publication bias. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes, which is a universal consideration in all medical research.

Key Studies & References

  1. Treatments for spasticity and pain in multiple sclerosis: a systematic review
  2. WHO Model List of Essential Medicines (EML) - Diazepam Entry
  3. Diazepam - StatPearls (Source for general clinical uses, pharmacokinetics, and approved indications)

Frequently Asked Questions (FAQ)

Common questions about Bensedin (FAQ)


Q: How quickly does Bensedin start to have an effect?

A: Official information indicates that Bensedin is absorbed rapidly after being taken orally. Studies have shown that the concentration of the drug reaches its highest point in the bloodstream, known as peak plasma concentration, generally within one to one and a half hours. Taking the drug with food can potentially slow down this absorption process.


Q: What is the typical duration of Bensedin's effects?

A: The drug's elimination from the body is complex and occurs in multiple stages. According to official labeling, Bensedin itself has a long half-life, which can be up to 48 hours. Furthermore, its active chemical byproduct in the body, known as a metabolite, can remain in the system for even longer, sometimes up to 100 hours.


Q: Does Bensedin cause sleepiness during the day?

A: Regulatory documents list drowsiness and tiredness as commonly reported adverse effects. Because the drug may affect concentration, regulatory information indicates that the drug may cause drowsiness.


Q: Can Bensedin be stopped suddenly?

A: Regulatory information specifies that treatment should not be stopped abruptly, particularly following chronic use, as this may lead to severe symptoms of withdrawal. Official prescribing information specifies that the dosage should be reduced gradually over time.


Q: Can Bensedin affect performance at work or school?

A: Due to its function as a central nervous system depressant, the drug can cause effects such as drowsiness, difficulty concentrating, and poor coordination. Regulatory guidance indicates that individuals should exercise caution when driving or operating complex machinery due to these effects.


Q: Does Bensedin interact with common over-the-counter pain relievers?

A: While regulatory warnings focus mainly on drugs that affect the central nervous system or the liver’s metabolism, regulatory documents do not specifically list interactions with common non-opioid pain relievers. All co-administration should be reviewed based on official product labeling.


Q: Does Bensedin cause problems with balance or coordination?

A: Yes, adverse effects listed in official documents include unsteadiness and a condition called ataxia, which is poor muscle coordination. This effect is noted to be more pronounced in certain populations, such as older adults.


Q: Can Bensedin be taken with a cold or flu medicine?

A: Caution is advised when using Bensedin alongside non-prescription products that can cause sedation. Warnings specifically note that combining the drug with certain cold or flu medicines, such as those containing sedating antihistamines, can increase the risk of profound central nervous system depression.


Q: Are there any common foods or drinks that should be avoided when using Bensedin?

A: Official regulatory advice strictly recommends avoiding the simultaneous ingestion of alcohol due to the high risk of increased central nervous system depressant effects. Some sources also advise against consuming grapefruit or grapefruit juice, as it is known to potentially interfere with how the medicine is processed by the body.


Q: Is Bensedin ever used for conditions other than those listed in the core uses?

A: Bensedin is officially approved for specific conditions, including anxiety, muscle spasms, seizures, and alcohol withdrawal. Official prescribing guidelines state that using the drug to treat certain phobic states, such as fear of open spaces, is listed as a contraindication.


Q: What should be done if an allergic reaction is suspected after taking Bensedin?

A: Official information indicates that immediate medical attention is necessary if symptoms of a severe allergic reaction are experienced. These symptoms include swelling of the face, lips, tongue, or throat, or any difficulty breathing.


Q: Do the effects of Bensedin vary significantly between different people?

A: Studies and regulatory literature indicate that the rate at which the body clears the drug can vary significantly between individuals. This variability is linked to genetic differences in certain liver enzymes, suggesting that people may process and respond to the medication differently.


Q: Is Bensedin used for short-term situations like fear of flying?

A: Official prescribing guidelines state that the use of this drug to treat phobic states, which includes specific situations like fear of flying, is listed as a contraindication. Official guidance indicates that the use of this medication is not recommended for mild or situational anxiety.


Q: What are the signs that Bensedin is beginning to wear off?

A: As the drug’s effects decline or during the tapering process, official descriptions of withdrawal symptoms suggest a return of the original condition. This may involve a return of the original symptoms, such as anxiety or insomnia, that the medication was being used for.


Q: Are there any genetic factors that influence how Bensedin works?

A: Regulatory-referenced literature confirms that genetic variations in liver enzymes, specifically those involved in metabolism like CYP2C19 and CYP3A4, can influence how the body processes Bensedin. These genetic factors can affect the amount of drug circulating in the bloodstream.


Q: Has Bensedin been studied in diverse patient populations?

A: Studies have been conducted that include certain special populations such as specific pediatric and older adult groups. Official labeling also notes that the variability in drug metabolism is partly due to genetic polymorphisms that show different frequencies across various ethnic and demographic groups.

How should Bensedin be stored and disposed of?

How to Store and Dispose of Bensedin (Diazepam) According to Official Labeling

Official labeling requires specific conditions for the storage and disposal of Bensedin (Diazepam) to maintain product integrity and prevent misuse.


Storage Requirements

Bensedin must be stored at room temperature, typically between 20 C and 25 C (68 F to 77 F), and must be protected from excess heat and moisture. The medication must be kept in the tightly closed container in which it was dispensed.

Crucially, due to its properties, Bensedin must be kept out of the sight and reach of children in a secure location.


Disposal Instructions

As a controlled substance, Bensedin should ideally be disposed of using an authorized drug take-back program or pharmacy collection point. If these options are unavailable, the FDA advises mixing the drug (if not on the flush list) with an undesirable substance, such as coffee grounds, placing the mixture in a sealed bag, and discarding it in household trash. Personal information should be removed from all packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bensedin found in:

A-Z Index: